Chemistry:DA-Phen

From HandWiki

DA-Phen, also known as dopamine–phenylalanine conjugate, is a synthetic dopamine prodrug which is under preclinical evaluation.[1][2][3][4][5][6][7] Dopamine itself is hydrophilic and is unable to cross the blood–brain barrier, thus showing peripheral selectivity.[2] DA-Phen was developed as a dopamine prodrug that would allow for entry into the central nervous system via passive diffusion and/or active transport.[1][2]

DA-Phen is a conjugate of dopamine and the amino acid phenylalanine (Phe or Phen).[1][2] It is slowly cleaved by brain enzymes (t½ = 460 minutes) to yield free dopamine but is also rapidly hydrolyzed in human blood plasma (t½ = 28 minutes).[2] The drug was intended as a prodrug but may also directly interact with the dopamine D1-like and/or D2-like receptors.[1][5][4][6] DA-Phen has shown centrally mediated effects in animals, including increased cognitive flexibility, improved spatial learning and memory, antidepressant- and anxiolytic-like effects, and decreased ethanol intake.[1][7][5]

Other analogues, such as DA-Trp and DA-Leu, have also been developed and studied.[4]

See also

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 "Small endogenous molecules as moiety to improve targeting of CNS drugs". Expert Opinion on Drug Delivery 14 (1): 93–107. January 2017. doi:10.1080/17425247.2016.1208651. PMID 27367188. "Recently, DA has been conjugated with Phe (DA-Phen, Fig 2A) and other Phe mono substituted moieties obtaining related neurotransmitter derivatives capable of carrying DA into the CNS [35,36]. In particular, the physicochemical properties of DA-Phen, e.g. molecular weight and LogD, are favourable for its ability in crossing biological membranes [35]. The aptitude of DA-Phen to reach the CNS has been assessed in a combined approach in vitro, using the PAMPA-BBB and Caco-2 models. Transport across the BBB substantially occurred through transcellular permeation, involving carrier-mediated processes. Molecular docking analysis evidenced that this conjugate interacts with the deep pocket of the identified D1 binding site of the human brain receptor [37]. Following administration on rats, DA-Phen showed a consistent enhancement in cognitive flexibility in naïve subjects, whereas in rats who are trained to alcohol self-administration the conjugate is able to reduce both ethanol intake and forced abstinence signs [38].". 
  2. ↑ 2.0 2.1 2.2 2.3 2.4 "Dopamine and Levodopa Prodrugs for the Treatment of Parkinson's Disease". Molecules 23 (1): 40. December 2017. doi:10.3390/molecules23010040. PMID 29295587. "1.5. Peptide Transport-Mediated Prodrugs Giannola et al. [80] have proposed a 2-amino-N-[2-(3,4-dihydroxyphenyl)-ethyl]-3-phenyl-propionamide dopamine prodrug (DA-PHEN) (Figure 10) [81]. It was synthesized by condensation of dopamine with a neutral amino acid to interact with the BBB endogenous transporters and readily enter the CNS. DA-PHEN undergoes slow cleavage by cerebral enzymes (t 1/2 460 min) and yields free dopamine in the brain, but it is rapidly hydrolyzed in human plasma (t 1/2 28 min). Chemical stability studies on DA-PHEN proved that no DA release happened in the gastrointestinal tract, also the prodrug can cross through a simulated intestinal mucosal membrane. Recently, De Caro et al. [81] studied in vitro the ability of DA-PHEN to penetrate the CNS. The team used in their study parallel artificial permeability assay (PAMPA) and Caco-2 models. Despite the relatively low molecular weight (300.35 Da) and the estimated experimental value [80] of log DPh 7.4 (0.76) of DA-PHEN which indicates good potential for passage through biological membranes, they noticed very limited transport through PAMPA-BBB [81]. In fact, the apparent permeability was 3.2 × 107 cm/s, indicating low capacity of DA-PHEN to penetrate BBB by passive transcellular route. Transport trials via Caco-2 cells showed marked increase of DA-PHEN flux with regard to that calculated in PAMPA-BBB system. However, high penetration rates seen in DA-PHEN cannot be obtained only by the simple diffusion, but may also involve carrier mediated transport [82].". 
  3. ↑ "Development of Prodrugs for Treatment of Parkinson's Disease: New Inorganic Scaffolds for Blood-Brain Barrier Permeation". Journal of Pharmaceutical Sciences 111 (5): 1262–1279. May 2022. doi:10.1016/j.xphs.2022.02.005. PMID 35182542. "DA-PHEN (XXXXI): can be classified as a dopamine prodrug, belonging to the group of peptide transport-mediated prodrugs. It can easily cross the BBB and reach the CNS; it has been proposed that the molecule can also act as a per se drug which modulates cognitive performances correlated with dopaminergic neurotransmission. Preclinical studies will be the next step to be performed.". 
  4. ↑ 4.0 4.1 4.2 "Design, synthesis and preliminary evaluation of dopamine-amino acid conjugates as potential D1 dopaminergic modulators". European Journal of Medicinal Chemistry 124: 435–444. November 2016. doi:10.1016/j.ejmech.2016.08.051. PMID 27597419. 
  5. ↑ 5.0 5.1 5.2 "Studies on a new potential dopaminergic agent: in vitro BBB permeability, in vivo behavioural effects and molecular docking evaluation". Journal of Drug Targeting 23 (10): 910–925. December 2015. doi:10.3109/1061186X.2015.1035275. PMID 26000952. 
  6. ↑ 6.0 6.1 "Assessment of in vivo organ-uptake and in silico prediction of CYP mediated metabolism of DA-Phen, a new dopaminergic agent". Computational Biology and Chemistry 71: 63–69. December 2017. doi:10.1016/j.compbiolchem.2017.09.012. PMID 28985485. 
  7. ↑ 7.0 7.1 "Effects of DA-Phen, a dopamine-aminoacidic conjugate, on alcohol intake and forced abstinence". Behavioural Brain Research 310: 109–118. September 2016. doi:10.1016/j.bbr.2016.05.006. PMID 27155501. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:DA-Phen&oldid=4036140"